Protagonist Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-129.00
279.00
-78.00
-127.00
-128.00
-65.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
146.00
-122.00
-19.00
-7.00
-3.00
-19.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
57.00
184.00
-70.00
-108.00
-107.00
-72.00
Cash Flow from Investing Activities
-49.00
-299.00
-39.00
91.00
-15.00
-90.00
Cash Flow from Financing Activities
22.00
25.00
170.00
18.00
129.00
247.00
Net Cash Inflow / Outflow
31.00
-89.00
60.00
2.00
6.00
84.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Protagonist Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-129.311
-210.304
81.00
38.51%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
146.209
9.089
137.00
1508.64%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
57.671
-155.503
212.00
137.09%
Cash Flow from Investing Activities
-49.332
140.34
-189.00
-135.15%
Cash Flow from Financing Activities
22.864
23.117
-1.00
-1.09%
Net Cash Inflow / Outflow
31.203
7.954
24.00
292.29%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is -68.68% vs 362.19% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
57.67
184.15
-68.68%






